

Filing pursuant to Rule 425 under the  
Securities Act of 1933, as amended  
Deemed filed under Rule 14a-12 under the  
Securities Exchange Act of 1934, as amended

Filer: International Flavors & Fragrances Inc.

Subject Company: International Flavors & Fragrances Inc.

Filer's Commission File Number: 1-4858

Date: January 21, 2020



**IFF + N&B**

New Global Integrated  
Solutions Leader

**iff**

## TEAM INTRODUCTION

Marc Doyle – CEO DuPont

Darrell Ford - SVP & CHRO DuPont

Matthias Heinzl – President DuPont N&B

Barbara Pandos - Chief Communications Officer DuPont

Sarah-Jane Jumppanen - Global Communications Director DuPont N&B



# IFF'S TRANSFORMATIONAL JOURNEY

Achieving our vision by building on our legacy to redefine our future

	2015	2019E	2021E+
	<b>iff</b>	<b>iff + FRUTAROM</b>	<b>iff + DuPont Nutrition &amp; Biosciences</b>
<b>Sales Evolution</b>	~\$3B	~\$5B	~\$11B
<b>Employees</b>	6,700	13,000	23,000
<b>R&amp;D Spend</b>	~\$250M	~\$350M	>\$550M
<b># of Granted Patents</b>	~1,300	~1,600	~9,000
<b>Differentiated Solutions</b>	Specialized provider	Technical bundle	Integrated Solutions
<b>Customers</b>	~3,000	~39,000	>40,000
<b>Positioning &amp; Capabilities</b>	#4 Taste & Scent	#2 Taste & Scent	#1 & #2 Taste, Scent, Nutrition, Cultures, Enzymes, Probiotics, Soy Proteins


# COMPELLING COMBINATION

Complementary portfolios that build on the best of both capabilities & talent



A global leader in taste, scent and nutrition

- #2 in Flavor & Fragrances
- Leading natural capabilities
- Creative and innovation-led organization
- Broadest customer base with 60% of sales to local & regional customers (45% in Emerging Markets)
- >80% sales outside North America
- Well positioned in fast-growing adjacencies (i.e., Food Protection, Inclusions, Health ingredients, Cosmetic Actives)
- Deep commitment to sustainability
- World-class operations & supply chain



**COMBINED COMPANY**

**DuPont**  
Nutrition & Biosciences

Leading value-added ingredients & solutions provider

- #1 or 2 positions in Nutrition, Cultures, Enzymes, Probiotics, Soy Proteins
- Customer-led innovation and R&D focused organization
- Deep customer relationships across food, nutrition, pharma and HPC customers
- Extensive global sales (with >60% outside North America) and applications capability
- Deep commitment to sustainability and product stewardship
- World-class operations and supply chain



<sup>(1)</sup> Before anticipated benefit of cost synergies

# INTRODUCTION TO DUPONT N&B

Innovation-driven portfolio of high-value, specialty ingredient businesses

## Global Leader

**10,000+**  
employees

**70+**  
manufacturing sites

**30+**  
technology & innovation  
centers

**10,000+**  
customers

## Leading Position in Shared End Markets



Food & Beverage  
(Specialty Food Ingredients)



Dietary Supplements



Animal Nutrition



Home &  
Personal Care



Pharma  
Excipients

**#1 or #2 across  
active Food &  
Beverage and  
Nutrition segments**

**#1 in Probiotics,  
Enzymes, Cultures,  
and Soy Protein**

## Strong Financial Profile



(1) Operating EBITDA is on a pro forma basis and is defined as earnings (i.e. income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, nonoperating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and excluding significant items.

# DUPONT N&B BUSINESS OVERVIEW

Innovation-driven portfolio of high-value, specialty ingredient businesses

Nutrition & Biosciences Portfolio			
	Health & Biosciences 39%	Food & Beverage 48%	Pharma Solutions 13%
Business Overview	World-leading bioscience innovator serving attractive markets with sustainable and high-performance solutions	Broadest portfolio of natural and plant-based specialty food ingredients	Global leader of functional cellulosic polymers & seaweed derived excipients for pharma & dietary supplements
Product Segments	<ul style="list-style-type: none"> <li>• Probiotics, HMO, Fibers</li> <li>• Cultures, Food Enzymes and Protection</li> <li>• Home &amp; Personal Care Enzymes</li> <li>• Animal Feed Enzymes &amp; Nutrition (probiotics)</li> <li>• Biorefinery Enzymes</li> <li>• Microbial Control</li> </ul>	<ul style="list-style-type: none"> <li>• Functional Solutions</li> <li>• Protein Solutions</li> <li>• Emulsifiers &amp; Sweeteners</li> </ul>	<ul style="list-style-type: none"> <li>• Controlled and immediate release</li> <li>• API (Alginates)</li> </ul>
Key Products/ Brands	<ul style="list-style-type: none"> <li>• HOWARU®</li> <li>• CARE4U™</li> <li>• LITESSE®</li> <li>• FIBRIM®</li> <li>• AXTRA® PHY</li> <li>• GENENCARE®</li> <li>• KATHON®</li> <li>• PREFERENZ®</li> <li>• SILVADUR™</li> <li>• XCELIS™</li> <li>• YO-MIX®</li> <li>• HOLDBAC®</li> <li>• CHOOZIT®</li> </ul>	<ul style="list-style-type: none"> <li>• CREMODAN®</li> <li>• GRINDSTED®</li> <li>• RECODAN™</li> <li>• DIMODAN®</li> <li>• PANODAN®</li> <li>• XIVIA®</li> <li>• SUPRO®</li> <li>• TRUPRO®</li> </ul>	<ul style="list-style-type: none"> <li>• AC-DI-SOL®</li> <li>• AQUACOAT®</li> <li>• AVICEL®</li> <li>• ETHOCEL™</li> <li>• METHOCEL™</li> <li>• POLYOX™</li> <li>• SEAGEL®</li> </ul>

Based on DuPont N&B's 2018 pro forma net sales.

## WHY IS DUPONT N&B ATTRACTIVE?

Creating a global value-added ingredients & solutions provider

- ✓ Proven leader and trusted partner with our own customers
- ✓ Deep focus on consumer-driven end markets
- ✓ Passionate commitment to a science-led, innovation-first culture
- ✓ Complementary capabilities & product portfolio with essentially no overlap
- ✓ Shares our dedication to sustainable practices, development and safety

**A business suited to partner alongside IFF to redefine our industry and become an invaluable partner for our customers**



# STRENGTHENING OUR VALUE PROPOSITION

Enhancing our capabilities to be an invaluable partner

## STRATEGIC RATIONALE

## VALUE PROPOSITION



**BROADENS  
CATEGORY EXPOSURE**

- Expands breadth of capabilities
- #1 or #2 position across high-value ingredients



**EXPANDS R&D  
CAPABILITIES & EXPERTISE**

- Best-in-class R&D and innovation capabilities and strongest industry pipeline to develop proactive solutions
- Talent with both creative and scientific expertise
- Largest R&D spend annually in industry at \$>550M
- More than 9,000 patents as combined company


















**DIFFERENTIATED INTEGRATED  
SOLUTIONS**

- Stronger & broadest differentiated product offerings
- Ability to improve speed to market
- Greater simplification of supply chain

# LEADER ACROSS ATTRACTIVE MARKETS

Breadth of capability & exposure establishes strong competitive position

Category Leader Position		IFF + DuPont N&B	Peer 1	Peer 2	Peer 3	Peer 4	Peer 5	Peer 6
Participates in the category								
Food & Beverage	Functional Solutions <sup>(1)</sup>		✓	✓				
	Emulsifiers & Lecithin			✓				
	Sweeteners <sup>(2)</sup>		✓					
	Plant Protein <sup>(2)</sup>			✓				
Health & BioScience	Cultures		✓					
	Probiotics			✓		✓		
	Enzymes		✓	✓				✓
	Animal Nutrition <sup>(1)</sup>	✓	✓				✓	✓
Pharma	Excipients			✓				
	Nutraceuticals <sup>(1)</sup>	✓	✓		✓	✓		
Flavor & Fragrance	Flavors			✓		✓		
	Fragrances					✓		
	Cosmetic Ingredients <sup>(1)</sup>	✓	✓		✓	✓		

**Evolving Customer Demand For More Integrated Solutions**

9 Source: Company Information  
 1. Functional solutions, Animal Nutrition, Nutraceuticals and Cosmetic Ingredients are widely defined categories with limited traditional "leadership"  
 2. In relevant segments

# TECHNOLOGY & INNOVATION

Expanded capabilities through R&D and innovation platforms

## Focused Technology & Innovation Platforms

 NATURALS & BEYOND	 DELIVERY SYSTEMS	 MODULATION
 BIOTECHNOLOGY	 FOOD SCIENCE & APPLICATION	 PHARMA EXCIPIENTS SCIENCE
 INGREDIENTS	 ACTIVE COSMETICS	 HEALTH & NUTRITION
 PROCESS TECHNOLOGY	 ADVANCED ANALYTICAL SCIENCE	 REGULATORY AFFAIRS & PRODUCT STEWARDSHIP

CHEMISTRY & MATERIAL SCIENCE

SUSTAINABILITY

## Snapshot of Capabilities & Expertise

**50+**

Research, Creative & Application  
Centers

**30+**

Human Clinical Trials In  
Flight

**100s**

Flavorists, Scent Design Managers  
and Perfumers, Chefs

**3,000+**

Scientists, Engineers,  
Technologists & Application

**>12,000**

Total Patents Granted & Filed

**40+**

Strategic University  
Partnerships

**>80**

Perfumers



# DIFFERENTIATED & AUGMENTED CAPABILITIES

Complementary capabilities and expertise in Fabric, Home & Personal Care

## Illustrative Product Examples

Fabric Care	Personal Care	Fragrance Ingredients
<p><b>Superior Cold Water Laundry Detergent</b></p>  <ul style="list-style-type: none"> <li>● <b>Enzymes</b> (Fluidity, Stain removal, Malodor)</li> <li>● <b>Microbial Control</b> (Antimicrobial &amp; shelf-life)</li> <li>● <b>Fragrance</b> (Scent &amp; odor coverage)</li> <li>● <b>Encapsulation</b> (Fit-for-purpose delivery and performance)</li> </ul>	<p><b>Improved Shampoo Formula</b></p>  <ul style="list-style-type: none"> <li>● <b>Personal Care Natural Additives</b> (Renewable moisturizing actives)</li> <li>● <b>Enzymes</b> (Fluidity, Stain removal, Malodor)</li> <li>● <b>Microbial Control</b> (Antimicrobial &amp; shelf-life)</li> <li>● <b>Fragrance</b> (Scent &amp; odor coverage)</li> <li>● <b>Encapsulation</b> (Delivery &amp; performance)</li> <li>● <b>Actives &amp; Antioxidants</b> (Clean label, shelf-life)</li> <li>● <b>Natural Color</b> (clean label)</li> </ul>	<p><b>More Secure &amp; Robust Ingredient Pipeline</b></p>  <ul style="list-style-type: none"> <li>● <b>Libraries</b> (Extensive Portfolio)</li> <li>● <b>Crispr CAS</b> (Targeted Gene Editing)</li> <li>● <b>Enzymes</b> (Optimizing Synthetic Processes)</li> <li>● <b>Biotechnology</b> (De-Risking Supply)</li> <li>● <b>New Molecule Discovery</b> (Scent Ingredients)</li> <li>● <b>Green Chemistry</b> (Consumer Friendly Processes)</li> <li>● <b>Renewability</b> (Environmentally Responsible Sourcing)</li> <li>● <b>Natural or Natural Derived</b> (Consumer Friendly Materials)</li> </ul>

Strengthens product differentiation & accelerates speed-to-market

# TRANSACTION BENEFITS ALL STAKEHOLDERS

**Competitive and thorough process leading to the selection of IFF**

## Significant value creation opportunities

- Compelling growth profile benefitting stakeholders and attractive value creation for shareholders over the short, medium and long term
- Will deliver **~\$300 million in run-rate cost synergies** and **>\$400 million in run-rate growth synergies\***
- Creates the industry's broadest technology portfolio

## Strong Corporate Governance

- Andreas Fibig to serve as Chairman & CEO
- Balanced board with equal composition from IFF and DuPont; Breen as Lead Independent Director
- Experienced senior leadership team with representation from both companies

**Advances DuPont strategy of active portfolio management to unlock shareholder value**

## Our People

Opportunities for employees to advance in a new market-leading company

\*Expect to achieve run rates year 3 after close



## APPROACH FOR N&B INTEGRATION

Deal close not expected until end of Q1 2021

- IFF and N&B are highly **complementary companies**
- We see value in **our unique skills** working together
- Closing is not expected until 2021, and we have **ample time to plan**
- First milestone announced 12/19: **Rich O’Leary appointed to lead integration** for IFF<sup>(1)</sup>
- For DuPont N&B, **Angela Naef appointed to lead integration**<sup>(1)</sup>
- We are **committed to learn** from Frutarom as we complete integration in 2H 2020
- Creating a culture of **creativity, science, innovation, sustainability & execution**

**We Will Keep You Informed Along The Way**

# WHAT DOES THIS MEAN FOR YOU

Need to delivery on our 2020 objectives



## BUSINESS AS USUAL

- Nothing changes right now. 2020 is all about IFF.
- IFF and N&B remain independent companies until transaction close
- Our goals, priorities and tasks remain the same
- Let's keep focus on executing our strategy and serving our customers



## ONGOING TEAM DIALOGUE

- We will keep you updated on integration as we have new information to share
- Expect senior leadership visits throughout 2020
- Your team leads will continue regular check-in meetings and updates
- Always reach out to your manager if you have questions or concerns



## EXCITING OPPORTUNITIES AHEAD

- Together we have the opportunity to redefine our industry
- We will be a clear industry leader
- Significant opportunities for employees, customers & shareholders
- Bring our vision to life!

**2020 Execution Is Key To Our Future Success**

**iff**



**About IFF**

At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we're using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at [iff.com](#), [Twitter](#), [Facebook](#), [Instagram](#), and [LinkedIn](#).

**About DuPont**

DuPont (NYSE:DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at [www.dupont.com](#).

**About DuPont Nutrition & Biosciences**

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: [www.dupontnutritionandhealth.com](#) or [www.biosciences.dupont.com](#).

**Additional Information and Where to Find It**

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"). In connection with the proposed combination of Nutrition & Biosciences, Inc. ("N&Bco"), a wholly owned subsidiary of DuPont de Nemours, Inc. ("DuPont"), and International Flavors & Fragrances Inc. ("IFF"), which will immediately follow the proposed separation of N&Bco from DuPont (the "proposed transaction"), N&Bco and IFF intend to file relevant materials with the SEC, including a registration statement on Form S-4 that will include a proxy statement/prospectus relating to the proposed transaction. In addition, N&Bco expects to file a registration statement in connection with its separation from DuPont. **INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENTS, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT IFF, N&BCO AND THE PROPOSED TRANSACTION.** A definitive proxy statement will be sent to shareholders of IFF seeking approval of the proposed transaction. The documents relating to the proposed transaction (when they are available) can be obtained free of charge from the SEC's website at [www.sec.gov](#). Free copies of these documents, once available, and each of the companies' other filings with the SEC may also be obtained from the respective companies by contacting the investor relations department of DuPont or IFF at the following:

**IFF Contact Information**

Michael DeVeau  
Michael.DeVeau@iff.com  
+1 212-708-7164

**DuPont Contact Information**

**DuPont Investors:**  
Lori Koch  
Lori.d.koch@dupont.com  
+1 302-999-5631

**Media:**  
Dan Turner  
Daniel.a.turner@dupont.com  
+1 302-996-8372

# CAUTIONARY STATEMENT

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the proposed transaction, the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding DuPont's, IFF's and N&Bco's future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. There are several factors which could cause actual plans and results to differ materially from those expressed or implied in forward-looking statements. Such factors include, but are not limited to, (1) the parties' ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction, (2) changes in relevant tax and other laws, (3) any failure to obtain necessary regulatory approvals, approval of IFF's shareholders, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the proposed transaction, (4) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction, (5) risks and costs and pursuit and/or implementation of the separation of N&Bco, including timing anticipated to complete the separation, any changes to the configuration of businesses included in the separation if implemented, (6) risks related to indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company ("Historical EID") in connection with the distribution of Corvea Inc. on June 1, 2019 (the "Corvea Distribution"), (7) potential liability arising from fraudulent conveyance and similar laws in connection with DuPont's distribution of Dow Inc. on April 1, 2019 and/or the Corvea Distributions (the "Previous Distributions"), (8) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corvea Distribution, related to the transfer of certain levels of assets and businesses, (9) uncertainty as to the long-term value of DuPont common stock, (10) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade, (11) inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with the accounting principles generally accepted in the United States of America and related standards, or on an adjusted basis, (12) the integration of IFF and its Frutarom business and/or N&Bco being more difficult, time consuming or costly than expected, (13) the failure to achieve expected or targeted future financial and operating performance and results, (14) the possibility that IFF may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames or at all or to successfully integrate Frutarom and N&Bco, (15) customer loss and business disruption being greater than expected following the proposed transaction, (16) the impact of divestitures required as a condition to consummation of the proposed transaction as well as other conditional commitments, (17) legislative, regulatory and economic developments; (18) an increase or decrease in the anticipated transaction taxes (including due to any changes to tax legislation and its impact on tax rates (and the timing of the effectiveness of any such changes)), (19) potential litigation relating to the proposed transaction that could be instituted against DuPont, IFF or their respective directors, (20) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (21) negative effects of the announcement or the consummation of the transaction on the market price of DuPont's and/or IFF's common stock, (22) risks relating to the value of the IFF shares to be issued in the transaction and uncertainty as to the long-term value of IFF's common stock, (23) risks relating to IFF's ongoing investigations into improper payments made in Frutarom businesses principally operating in Russia and the Ukraine, including expenses incurred with respect to the investigations, the cost of any remedial measures or compliance programs arising out of the investigations, legal proceedings or government investigations that may arise relating to the subject of IFF's investigations, and the outcome of any such legal or government investigations, such as the imposition of fines, penalties, orders, or injunctions, (24) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, including with respect to IFF's ongoing investigations into improper payments made in Frutarom businesses principally operating in Russia and the Ukraine, (25) the impact of the outcome of legal claims, regulatory investigations and litigation, including any that may arise out of IFF's ongoing investigations into improper payments made in Frutarom businesses principally operating in Russia and the Ukraine, (26) the ability of N&Bco or IFF to retain and hire key personnel, (27) the risk that N&Bco, as a newly formed entity that currently has no credit rating, will not have access to the capital markets on acceptable terms, (28) the risk that N&Bco and IFF will incur significant indebtedness in connection with the potential transaction, and the degree to which IFF will be leveraged following completion of the potential transaction may materially and adversely affect its business, financial condition and results of operations, (29) the ability to obtain or consummate financing or refinancing related to the transaction upon acceptable terms or at all, and (30) other risks to DuPont's, N&Bco's and IFF's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Previous Distributions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could result in a significant operational event for DuPont, N&Bco or IFF, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's, N&Bco's or IFF's intellectual property rights; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks, as well as other risks associated with the proposed merger, will be more fully discussed in the registration statement and merger proxy on Form S-4 to be filed by IFF and the registration statement on Form 10 to be filed by N&Bco. While the list of factors presented here is, and the list of factors to be presented in any registration statement filed in connection with the transaction are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements. Further lists and descriptions of risks and uncertainties can be found in each of IFF's and DuPont's Form 10-Q for the period ended September 30, 2019 and each of IFF's and DuPont's respective subsequent reports on Form 10-Q, Form 10-K and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Any other risks associated with the proposed transaction will be more fully discussed in any registration statement filed with the SEC. While the list of factors presented here is, and the list of factors that may be presented in a registration statement of IFF or N&Bco would be, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on IFF's, DuPont's or N&Bco's consolidated financial condition, results of operations, credit rating or liquidity. None of IFF, DuPont nor N&Bco assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

## PARTICIPANTS IN THE SOLICITATION

This communication is not a solicitation of a proxy from any investor or security holder. However, DuPont, IFF and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction under the rules of the SEC. Information about the directors and executive officers of DuPont may be found in its Annual Report on Form 10-K filed with the SEC on February 11, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019. Information about the directors and executive officers of IFF may be found in its definitive proxy statement filed with the SEC on March 18, 2019. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the registration statements, prospectuses and proxy statement and other relevant materials to be filed with the SEC when they become available.